SIGA - SIGA's Tpoxx antiviral to undergo human testing for monkeypox in September - Bloomberg
- Tpoxx (tecovirimat), an antiviral medication from SIGA Technologies ( NASDAQ: SIGA ), will begin testing in humans as soon as September, Bloomberg reported.
- The drug is currently only approved for smallpox but is available as a treatment for smallpox under the U.S. FDA's Expanded Access program.
- Bloomberg said that the National Institute of Allergy and Infectious Disease is about the start one of three trials.
- The FDA recently stated the drug should be examined in a human trial, a position backed by several public health officials .
- SIGA ( SIGA ) shares are up ~226% year to date. They hit a 52-week high Friday .
For further details see:
SIGA's Tpoxx antiviral to undergo human testing for monkeypox in September - Bloomberg